thalidomide has been researched along with Immunoblastic Lymphadenopathy in 7 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Immunoblastic Lymphadenopathy: A disorder characterized by proliferation of arborizing small vessels, prominent immunoblastic proliferations and amorphous acidophilic interstitial material. Clinical manifestations include fever, sweats, weight loss, generalized lymphadenopathy and frequently hepatosplenomegaly.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL." | 5.39 | Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. ( Beckers, MM; Huls, G, 2013) |
| "Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL." | 1.39 | Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. ( Beckers, MM; Huls, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broccoli, A | 1 |
| Pellegrini, C | 1 |
| Celli, M | 1 |
| Argnani, L | 1 |
| Agostinelli, C | 1 |
| Pileri, S | 1 |
| Zinzani, PL | 1 |
| Chaoui, D | 1 |
| Bouallegue, S | 1 |
| Arakelyan, N | 1 |
| Genet, P | 1 |
| Aljijakli, A | 1 |
| Sutton, L | 1 |
| Townsend, W | 1 |
| Johnson, RJ | 1 |
| Pottinger, BT | 1 |
| Counsell, N | 1 |
| Smith, P | 1 |
| Chadwick, H | 1 |
| Evans, K | 1 |
| Wickham, C | 1 |
| Rudin, CE | 1 |
| Gottardi, M | 1 |
| Danesin, C | 1 |
| Canal, F | 1 |
| Dei Tos, AP | 1 |
| Stefani, PM | 1 |
| Calistri, E | 1 |
| Salvadori, U | 1 |
| Gherlinzoni, F | 1 |
| Qin, Y | 1 |
| Shi, YK | 1 |
| He, XH | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Zhou, SY | 1 |
| Liu, XF | 1 |
| Liu, P | 1 |
| Yang, S | 1 |
| Zhou, LQ | 1 |
| Han, XH | 1 |
| Yao, JR | 1 |
| Beckers, MM | 1 |
| Huls, G | 1 |
| Strupp, C | 1 |
| Aivado, M | 1 |
| Germing, U | 1 |
| Gattermann, N | 1 |
| Haas, R | 1 |
1 trial available for thalidomide and Immunoblastic Lymphadenopathy
| Article | Year |
|---|---|
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease P | 2016 |
6 other studies available for thalidomide and Immunoblastic Lymphadenopathy
| Article | Year |
|---|---|
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2014 |
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female | 2014 |
Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell, Pe | 2008 |
[Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo | 2010 |
Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
Topics: Antineoplastic Agents, Hormonal; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Ce | 2013 |
Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Fatal Outcome; Female; Humans; Immunobla | 2002 |